BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2248685)

  • 1. Cefpodoxime: comparable evaluation with other orally available cephalosporins. With a note on the role of beta-lactamases.
    Cullmann W; Dick W
    Zentralbl Bakteriol; 1990 Sep; 273(4):501-17. PubMed ID: 2248685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.
    Cullmann W; Dick W; Stieglitz M; Opferkuch W
    Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
    Bauernfeind A; Jungwirth R
    Infection; 1991; 19(5):353-62. PubMed ID: 1800377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
    Knothe H; Shah PM; Eckardt O
    Infection; 1991; 19(5):370-6. PubMed ID: 1800379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.
    Wise R; Andrews JM; Ashby JP; Thornber D
    J Antimicrob Chemother; 1990 Apr; 25(4):541-50. PubMed ID: 2351624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Infection; 1991; 19(5):363-9. PubMed ID: 1800378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiological evaluation of cefpodoxime proxetil.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.
    Kayser FH
    Infection; 1994; 22(5):370-5. PubMed ID: 7843823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].
    Bauernfeind A; Jungwirth R; Schweighart S; Theopold M
    Infection; 1990; 18 Suppl 3():S155-67. PubMed ID: 2079378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
    Chantot JF; Mauvais P
    Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability in the presence of widespread beta-lactamases. A prerequisite for the antibacterial activity of beta-lactam drugs.
    Schito GC; Pesce A; Debbia EA
    Drugs; 1994; 47 Suppl 3():1-8; discussion 8-9. PubMed ID: 7518761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative study of the antibacterial activity of cefpodoxime against enterobacteria producing beta lactamases].
    Siebor E; Cordin X; Delpech N; Duez JM; Kazmierczak A
    Pathol Biol (Paris); 1990 May; 38(5):331-5. PubMed ID: 2367149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of cefpodoxime in vitro.
    Liu YC; Huang WK; Cheng DL
    Chemotherapy; 1997; 43(1):21-6. PubMed ID: 8996737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).
    Neu HC; Chin NX; Labthavikul P
    Antimicrob Agents Chemother; 1986 Sep; 30(3):423-8. PubMed ID: 3490827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.
    Babini GS; Yuan M; Livermore DM
    Antimicrob Agents Chemother; 1998 May; 42(5):1168-75. PubMed ID: 9593145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-spectrum beta-lactamase-mediated resistance among bacterial isolates recovered from ocular infections.
    Jayahar Bharathi M; Ramakrishnan R; Ramesh S; Murugan N
    Ophthalmic Res; 2012; 47(1):52-6. PubMed ID: 21720185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.
    Knapp CC; Sierra-Madero J; Washington JA
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1896-8. PubMed ID: 3245701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluations of U-76,252 (CS-807): antimicrobial spectrum, beta-lactamase stability, and enzyme inhibition.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1987 Dec; 8(4):245-9. PubMed ID: 2856864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
    Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
    Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.